Erschienen in:
01.02.2007 | Letter to the editor
HO prevention and the combined therapeutic protocol—do we really need it?
verfasst von:
Kamil Cagri Kose, Oguz Cebesoy, Levent Altinel
Erschienen in:
International Orthopaedics
|
Ausgabe 1/2007
Einloggen, um Zugang zu erhalten
Excerpt
We would like to comment on the article by E.E. Pakos et al. entitled "Prevention of heterotopic ossification in high-risk patients with total hip arthroplasty: the experience of a combined therapeutic protocol" [
5]. First, we would like to congratulate the authors for their contribution to the relevant literature. In the authors’ study, ankylosing spondylitis, hypertrophic osteoarthritis, diffuse skeletal hyperostosis, biochemical factors, male sex and a previous history of heterotopic ossication are defined as risk factors [
5]. They also stated that this kind of study (combined radiotherapy and NSAID) has not been done before. They could not find a difference regarding the types of prosthesis, but found a statistically significant incidence of HO in females and in patients of osteoarthritis secondary to congenital hip dysplasia [
5]. Heterotopic ossification (HO) is a common problem, especially after total hip replacement (THR) or after fracture treatment around the hip. …
